OncLive

Everolimus Reduces Breast Cancer Effects in Bone
Ob.Gyn. News Digital Network
Adding everolimus to exemestane for the treatment of estrogen receptorā€“positive advanced breast cancer that is refractory to nonsteroidal aromatase inhibitors has beneficial effects on bone turnover and breast cancer progression in bone, according to ...
Updated BOLERO-2 Data Support Efficacy of Everolimus in Breast CancerOncLive
Novartis launches breast cancer drug Afinitor in UKZenopa
Afinitor's new UK indication launchedInPharm
GenomeWeb
all 11 news articles »